R&D into Deep-Seated Tumor Treatment Using BNCT
First written in FY2025. 11 of 12 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-10-19.
1 other company's latest entry also says "Advanced".
- 2026-10-19AdvancedShare Issuance and Disposal
「今後、藤田医科大学および関係各社との契約締結を通じ、深部がん治療の実現に向けた研究開発を進める予定であり、FBPA-PET*4評価、非臨床試験および臨床試験等の関連費用として420百万円を充当する予定です。」
深部がん治療の研究開発について、FBPA-PET評価、非臨床試験および臨床試験等への420百万円の充当予定を具体化した。 - 2026-10-02Advancedfinance.yahoo.co.jpThere has been concrete progress in the clinical study investigating the uptake of 18F-FBPA in deep-seated cancers, with an agreement to conduct the study having been signed.
- FY2026AdvancedAnnual report
「In January 2026, an agreement was entered into concerning the introduction of a BNCT treatment system and a BNCT dose calculation program for the research and development of deep-seated cancer treatment.」
For the research and development of deep-seated cancer treatment, the project advanced to the execution of an agreement with Fujita Health University and SUMITOMO HEAVY INDUSTRIES,LTD. for the introduction of a BNCT treatment system and dose calculation program. - FY2026-H1AdvancedAnnual report
「As a result, treatment of thoracic malignancies was successful in mice modeling malignant pleural mesothelioma while suppressing adverse effects, resulting in a substantial improvement in survival.」
Research on a PVA formulation for deep-seated tumor treatment confirmed successful treatment and improved survival in mice modeling malignant pleural mesothelioma. - FY2025First statedAnnual report
「BNCT has traditionally been limited to treating tumors located at a maximum depth of 6–8 cm from the body surface because of restrictions on the depth to which neutrons can reach safely and effectively. With the aim of expanding its use to deeper tumors, in December 2024 we entered into a memorandum of understanding with Fujita Academy, Atransen Pharma Co., Ltd., SUMITOMO HEAVY INDUSTRIES,LTD. and Fujita Corporation to promote research and development of BNCT treatment for deep-seated tumors, and began initiatives for research and development of deep-seated tumor treatment to further advance BNCT.」
Research and development aimed at treating deeper tumors beyond the conventional depth limitations began under a memorandum of understanding with 4 parties.